Saniona publishes its interim report for the first quarter of 2023
|Q1 2023 (2022)|
|Revenue was SEK 2.2 M (6.6 M)|
|Operating profit/loss was SEK -21.1 M (-133.2 M)|
|Net profit/loss was SEK -21.7 M (-133.4 M)|
|Basic earnings/loss per share was SEK -0.35 (-2.14)|
|Diluted earnings/loss per share were SEK -0.35 (-2.14)|
Business highlights in Q1 2023
- On January 17, Saniona announced successful preclinical in vivo validation for treatment of migraine in the Cephagenix joint venture program.
- On February 25, Saniona announced that its partner Medix received favorable opinion for tesofensine for the treatment of obesity and weight management in Mexico.
Significant events after the reporting period
- There have been no events after the reporting period.
Comments from the CEO
“Good progress on partnering negotiations and a potential approval of tesofensine in Mexico for treatment of obesity.”